Literature DB >> 10233906

Human monocytes constitutively express membrane-bound, biologically active, and interferon-gamma-upregulated interleukin-15.

T Musso1, L Calosso, M Zucca, M Millesimo, D Ravarino, M Giovarelli, F Malavasi, A N Ponzi, R Paus, S Bulfone-Paus.   

Abstract

Interleukin-15 (IL-15) is a potent regulator of T-, B-, and natural killer cell proliferation and displays unusually tight controls of secretion. Even though IL-15 mRNA is constitutively expressed in monocytes/macrophages and is upregulated by a variety of stimuli, evidence for IL-15 cytokine secretion is only found exceptionally, eg, conditions of pathological, chronic inflammation. This raises the possibility that monocytes express membrane-bound IL-15 rather than secrete it. The current study explores this hypothesis. We demonstrate here that biologically active IL-15 is indeed detectable in a constitutively expressed, membrane-bound form on normal human monocytes, as well as on monocytic cell lines (MONO-MAC-6, THP-1, and U937), but not on human T or B cells (MT4, M9, C5966, JURKAT, DAUDI, RAJI, and Epstein-Barr virus-immortalized B-cell clones). Furthermore, cell surface-bound IL-15 is upregulated upon interferon-gamma stimulation. Interestingly, monocyte/macrophage inhibitory cytokines such as IL-4 and IL-13 fail to downregulate both constitutive and induced cell-surface expression of IL-15. Membrane-bound IL-15 does not elute with acetate buffer or trypsin treatment, suggesting that it is an integral membrane protein and that it is not associated with the IL-15 receptor complex. Finally, membrane-bound IL-15 stimulates T lymphocytes to proliferate in vitro, indicating that it is biologically active. These findings enlist IL-15 in the fairly small family of cytokines for which the presence of a biologically active membrane-bound form has been demonstrated (eg, IL-1, tumor necrosis factor-alpha, and IL-10) and invites the speculation that most of the biological effects of IL-15 under physiological conditions are exerted by the cell surface-bound form.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10233906

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  62 in total

1.  Production and distribution of interleukin 15 and its receptors (IL-15Ralpha and IL-R2beta) in the implant interface tissues obtained during revision of failed total joint replacement.

Authors:  S Saeed; P A Revell
Journal:  Int J Exp Pathol       Date:  2001-06       Impact factor: 1.925

2.  Natural killer cell engineering for cellular therapy of cancer.

Authors:  D R Shook; D Campana
Journal:  Tissue Antigens       Date:  2011-12

3.  Differential mechanisms of memory CD8 T cell maintenance by individual myeloid cell types.

Authors:  Loredana Frasca; Spencer W Stonier; Willem W Overwijk; Kimberly S Schluns
Journal:  J Leukoc Biol       Date:  2010-03-30       Impact factor: 4.962

4.  Effect of Anti-IL-15 Administration on T Cell and NK Cell Homeostasis in Rhesus Macaques.

Authors:  Maren Q DeGottardi; Afam A Okoye; Mukta Vaidya; Aarthi Talla; Audrie L Konfe; Matthew D Reyes; Joseph A Clock; Derick M Duell; Alfred W Legasse; Amit Sabnis; Byung S Park; Michael K Axthelm; Jacob D Estes; Keith A Reiman; Rafick-Pierre Sekaly; Louis J Picker
Journal:  J Immunol       Date:  2016-07-18       Impact factor: 5.422

Review 5.  The role of interleukin-15 in inflammation and immune responses to infection: implications for its therapeutic use.

Authors:  Pin-Yu Perera; Jack H Lichy; Thomas A Waldmann; Liyanage P Perera
Journal:  Microbes Infect       Date:  2011-10-25       Impact factor: 2.700

6.  Interleukin-15 enhances proliferation and chemokine secretion of human follicular dendritic cells.

Authors:  Minchan Gil; Seo-Jeong Park; Yoo-Sam Chung; Chan-Sik Park
Journal:  Immunology       Date:  2010-03-16       Impact factor: 7.397

7.  Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells.

Authors:  Chihaya Imai; Shotaro Iwamoto; Dario Campana
Journal:  Blood       Date:  2005-03-08       Impact factor: 22.113

8.  Rituximab-induced interleukin-15 reduction associated with clinical improvement in rheumatoid arthritis.

Authors:  César Díaz-Torné; M Angels Ortiz de Juana; Carme Geli; Elisabet Cantó; Ana Laiz; Héctor Corominas; Jordi Casademont; Josep M de Llobet; Cándido Juárez; César Díaz-López; Sílvia Vidal
Journal:  Immunology       Date:  2014-07       Impact factor: 7.397

9.  Epithelium derived interleukin 15 regulates intraepithelial lymphocyte Th1 cytokine production, cytotoxicity, and survival in coeliac disease.

Authors:  A Di Sabatino; R Ciccocioppo; F Cupelli; B Cinque; D Millimaggi; M M Clarkson; M Paulli; M G Cifone; G R Corazza
Journal:  Gut       Date:  2005-08-16       Impact factor: 23.059

10.  Dendritic cells drive memory CD8 T-cell homeostasis via IL-15 transpresentation.

Authors:  Spencer W Stonier; Lisa J Ma; Eliseo F Castillo; Kimberly S Schluns
Journal:  Blood       Date:  2008-09-23       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.